Clinical Trials Logo

Filter by:
  • Withdrawn  
  • « Prev · Page [2]
NCT ID: NCT01914575 Withdrawn - Clinical trials for Supraventricular Tachycardia

Dipole Density Mapping of Right and Left Atrial Supraventricular Tachycardia

DDRAMATIC-SVT
Start date: January 22, 2014
Phase: N/A
Study type: Interventional

Use of dipole density mapping to identify activation in complex supraventricular tachycardias

NCT ID: NCT01447394 Withdrawn - Clinical trials for Hepatitis C Virus (HCV)

Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

Start date: March 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if 48 weeks of therapy with Pegylated Interferon Lambda plus Ribavirin is effective and safe for a treatment of chronic hepatitis C (CHC) compared to therapy with Pegylated Interferon Alfa-2a plus Ribavirin.

NCT ID: NCT01326676 Withdrawn - Clinical trials for Cardiovascular Disease

Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial

PESCA
Start date: February 2011
Phase: Phase 3
Study type: Interventional

Medications that lower blood pressure and cholesterol are known to improve the shape and function of our blood vessels. These improvements include a reduction in the thickness of the wall of the carotid artery (the main artery that runs up the neck to supply the brain) and a reduction in the stiffness of arteries generally including the main central artery -the aorta. Such medications are in the polypill (the Red Heart Pill) that is being used in the UMPIRE Study. In UMPIRE, patients' reported adherence to taking the single, once daily polypill is being compared to adherence to medications taken as separate tablets (usual care).The aim of the PESCA sub-study is to see whether or not the polypill differs from 'usual care' in its direct effects on blood vessels as shown by ultrasound examination of the carotid arteries and assessment of central (aortic) blood pressure.

NCT ID: NCT00757055 Withdrawn - Clinical trials for Diastolic Heart Failure

If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure

Start date: December 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate whether the medicine ivabradine, a novel drug which slows the heart rate has a favourable effect on patients with diastolic heart failure. Ivabradine is a specific heart rate-lowering agent. It has a licence for treating patients with angina who are intolerant of agents such as beta blockers or whose angina is not adequately controlled. It has been shown to prolong exercise tolerance in these patients and to reduce the frequency of chest pain. Its mechanism of action is felt to be purely due to reducing heart rate, by as much as 10 beats per minute at rest, as well as by reducing the heart rate response to exercise. Patients with diastolic heart failure often complain of breathlessness on exertion which relates to the stiffness or lack of compliance of their heart i.e. the heart fails to relax rapidly enough to allow it to fill with blood between each heart beat. This may result in high pressure in the heart chamber which backs up in to the lungs and may be experienced as breathlessness. There is little evidence that any specific therapy benefits patients with this type of heart failure besides treating coexisting problems such as high blood pressure or angina. By slowing the heart rate down with ivabradine, the heart would have a longer time to fill during exercise which would make it more effective. This slowing of the heart rate may therefore relieve the breathlessness experienced on activity such as walking to the shops or up a flight of stairs etc.